Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 52, Issue 21, Pages 6790-6802Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm900648x
Keywords
-
Categories
Funding
- Fondation pour la Recherche Medicale, Nord-Pas-de-Calais [RAD07001EEA]
Ask authors/readers for more resources
Hydroxamates are valuable tools for chemical biology as well its interesting leads for medicinal chemistry. Although many hydroxamates display nanomolar activities against metalloproteases, only three hydroxamates have reached the market, among which is the HDAC inhibitor vorinostat. Failures in development are generally attributed to lack of selectivity, toxicity, or poor stability. To help medicinal chemists with respect to plasma stability, we have performed the first and preliminary study on structure-plasma stability for hydroxamates. We define some structural rules to predict or improve the plasma stability in the preclinical stage.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available